Friday, 19 December 2014

Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 

Eli Lilly and Company and Adocia announce a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes


Long-term Efficacy and Safety of Canagliflozin Over 104 Weeks in Patients Aged 55 to 80 Years With Type 2 Diabetes

Canagliflozin improved glycaemic control, reduced body weight and systolic BP, and was generally well tolerated in patients aged 55–80 years with T2DM over 104 weeks (Diabetes, Obesity and Metabolism)


Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors

The majority of long-duration T1D patients have detectable urine C-peptide levels. While the majority of patients are insulin microsecretors, some maintain clinically relevant endogenous insulin secretion for many years after the diagnosis of diabetes. Understanding this may lead to a better understanding of pathogenesis in T1D and open new possibilities for treatment (Diabetes Care)


Clinical predictors and time course of the improvement in ß–cell function with short-term intensive insulin therapy in patients with Type 2 diabetes

At baseline, shorter duration of diabetes and lower fasting glucose can identify patients most likely to benefit from short-term intensive insulin therapy. Most importantly, during therapy, responders had less hypoglycaemia from the third week onwards, despite lower glycaemia, suggesting that 2 weeks of intensive insulin therapy may be needed to improve endogenous islet function (Diabetic Medicine)

No comments:

Post a Comment